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Cytomegalovirus (CMV) is known to rapidly induce activation of nuclear factor B (NF-B) after infection
of fibroblast and macrophage cells. NF-B response elements are present in the enhancer region of the CMV
major immediate-early promoter (MIEP), and activity of the MIEP is strongly upregulated by NF-B in
transient-transfection assays. Here we investigate whether the NF-B-dependent pathway is required for
initiating or potentiating human and murine CMV replication in vitro. We show that expression of a dominant
negative mutant of the inhibitor of NF-B-alpha (IBM) does not alter the replication kinetics of human or
mouse CMV in cultured cells. In addition, mouse embryo fibroblasts genetically deficient for p65/RelA actually
showed elevated levels of MCMV replication. Mutation of all NF-B response elements within the enhancer of
the MIEP in a recombinant mouse CMV containing the human MIEP (hMCMV-ES), which we have previously
shown to replicate in murine fibroblasts with kinetics equivalent to that of wild-type mouse CMV, did not
negatively affect replication in fibroblasts. Taken together, these data show that, for CMV replication in
cultured fibroblasts activation of the canonical NF-B pathway and binding of NF-B to the MIEP are
dispensable, and in the case of p65 may even interfere, thus uncovering a previously unrecognized level of
complexity in the host regulatory network governing MIE gene expression in the context of a viral infection.
Cytomegalovirus (CMV), the prototypic betaherpesvirus,
shows sequential regulation of gene expression, as is the case
for all the members of family Herpesviridae (35). CMV repli-
cation begins with expression of the immediate-early (IE/)
proteins shortly after infection and is dependent upon the host
RNA polymerase. Expression of the CMV ie genes leads to
expression of viral transactivators that promote induction of
CMV early () genes and eventually late () genes, which are
expressed after DNA replication has been initiated. Transcrip-
tion of the major ie genes is controlled by the major immedi-
ate-early promoter (MIEP). The enhancer of the MIEP is a
highly complex region, and its activity depends on a diverse
number of positive and negative cis-acting elements. Although
the MIEP enhancers of mouse and human CMV (MCMV and
HCMV, respectively) show limited homology at the nucleotide
level, they share many common functional regulatory elements
(6, 13). The MIE proteins in HCMV and MCMV (IE1/IE2 and
IE1/IE3, respectively) have been shown to transactivate viral
and host gene expression as well as to regulate their own
expression through binding the MIEP (24, 30, 35, 46–48). The
MIEP enhancer of MCMV has been shown to play an impor-
tant yet dispensable role in initiation and potentiation of viral
replication in tissue culture (2) and more recently has been
found to be absolutely essential for in vivo growth (14). Re-
placement of the MIEP enhancer of MCMV with the paralo-
gous region from HCMV does not restrict replication of this
MCMV “enhancer swap” virus in tissue culture (2) or in vivo
(20). Directed mutagenesis of the HCMV MIEP has identified
the distal region of the enhancer as important for optimal
expression of IE genes and viral replication at low multiplicity
of infection (32, 33). Accordingly, expression of the MIE pro-
teins is required for efficient CMV growth (1, 17, 32, 34, 36),
and significant work has been done to delineate what specific
host factors are required for the initiation of ie gene expres-
sion.
The nuclear factor B (NF-B) family of transcription fac-
tors (including c-Rel, p65/RelA, RelB, p50/NF-B1, and p52/
NF-B2) is critical for mounting both innate and adaptive host
immune responses to pathogen infection through induction of
various “inflammatory” genes (15). Stimulation of cells with
agonists (including microbial products, viruses, or host cyto-
kines) can trigger various signal transduction pathways, ulti-
mately leading to activation of the inhibitor of NF-B kinase
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(IKK) complex (25). The “classical” IKK complex is composed
of IKK, IKK, and IKK, and the different roles of these
proteins in regulating the various NF-B family members when
responding to specific extracellular and intracellular signals is
a topic of heated study. In the case of the canonical NF-B
pathway (p50/p65 dependent) (15), the IKK complex can di-
rectly phosphorylate the inhibitor of NF-B-alpha (IB) on
two serine residues (S32 and S36), resulting in ubiquitin-me-
diated degradation of IB, translocation of p50/p65 to the
nucleus, and initiation of transcription through binding to
NF-B response elements. Importantly, although the majority
of studies in the literature to date have concentrated on
IKK-mediated activation of the canonical NF-B pathway,
newly identified homologues of the IKKs (40) and more de-
tailed elucidation of alternative or noncanonical NF-B signal-
ing pathways activated by tumor necrosis factor (TNF) family
cytokines (11, 26) highlights the enormous degree of complex-
ity, which ultimately results in the ability of this pathway to
translate the input of multiple stimuli into specific downstream
effects.
Infection of target cells by HCMV results in the modulation
of hundreds of cellular genes (7, 53), and increased numbers of
genes are upregulated when cells are exposed to replication-
inactivated HCMV (7). This result indicates that infection it-
self, in the absence of viral gene expression, activates multiple
cellular signaling pathways which lead to transcriptional induc-
tion of host and viral genes. It has been shown by several
groups that HCMV infection of primary fibroblasts and mono-
cyte-derived cell lines induces rapid (within 15 to 30 min)
translocation of NF-B to the nucleus and activates NF-B-
dependent transcription (9, 27, 43, 45, 53, 54). NF-B-respon-
sive elements present within 18-bp repeat sequences in the
MIEP enhancer bind NF-B and activate transcription of re-
porter genes (43, 45). IE1 and IE2 have been shown to trans-
activate both the p50 and p65 promoters, resulting in increased
levels of these proteins at later times (24 to 48 h) in the HCMV
replication cycle (55). Finally, it has recently been reported
that the overexpression of a constitutively active form of the
mitogen-activated protein kinase kinase kinase-1 results in in-
creased expression from the MIEP and that this condition
depends upon the NF-B binding elements in the 18-bp repeat
sequences (49).
Less is known regarding the activation and regulation of
NF-B in MCMV-infected cells. The MIEP of MCMV shows
high-level constitutive activity similar to its counterpart in
HCMV (13), and multiple consensus NF-B response ele-
ments are contained in its sequence (13, 44). Infection of
murine fibroblasts with MCMV has been shown to result in
translocation of NF-B (p50/p65) to the nucleus, similar to
that seen for HCMV (18). Taken together, these data suggest
a potentially important role for NF-B in regulating both hu-
man and murine CMV ie gene expression and replication.
On the basis of these studies, it has become accepted that
activation of NF-B upon a primary CMV infection “kick
starts” CMV replication at the immediate-early phase, and
transcriptional induction by CMV IE proteins of the p50/p65
subunits of NF-B may help to promote viral replication
through the early and late phases. Here we provide direct lines
of experimental evidence showing that mutating the NF-B
response elements in the MIEP and inhibition of the canonical
NF-B-dependent pathway does not hinder transcription-rep-
lication of HCMV or MCMV in cultured fibroblasts. Instead,
our results clearly demonstrate the regulatory robustness of
the CMV enhancer and suggest a potential p65-dependent
suppressive role of the NF-B pathway, thereby providing a
new framework for understanding the host regulatory network
of ie gene expression.
MATERIALS AND METHODS
Cells and virus. Normal human dermal fibroblasts (NHDF) from neonatal
foreskin (Clonetics, San Diego, Calif.) were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) (Gibco/BRL) supplemented with 10% fetal bovine
serum, 5 g of insulin per ml, and 1 ng of basic fibroblast growth factor (Sigma,
St. Louis, Mo.) per ml. Mouse NIH 3T3 cells (ATCC CRL1658) were grown in
DMEM supplemented with 10% newborn calf serum, and J774A.1 cells (ATCC
TIB 67) and immortalized p65/ and p65/ murine embryonic fibroblasts
(MEFs) (kind gift of A. Beg) (3) were grown in DMEM supplemented with 10%
fetal calf serum. MCMV (Smith strain, ATCC VR-1399) and bacterial artificial
chromosome (BAC)-derived MCMVs were propagated on NIH 3T3 cells for
generating viral stocks, and titers were determined by standard plaque assays in
NIH 3T3 cells. HCMV strain AD169-ATCC was acquired from the American
Type Culture Collection, and the Toledo strain was a kind gift from S. Starr
(passage 10). HCMV stocks were prepared by low-multiplicity-of-infection
(MOI) challenge of NHDF, combining sedimented extracellular virus (25,000 
g) with cell-associated virus (generated by cell sonication and removal of cell
debris by low-speed centrifugation). To avoid contamination of viral prepara-
tions by soluble cellular factors, HCMV was then pelleted (25,000  g) through
a 20% sorbitol cushion. HCMV titers were determined by limiting-dilution
plaque assays in NHDF.
Generation of MCMV mutants. Plasmid pIE111H carries the MCMV se-
quences from nucleotide (nt) 177008 (44) (EcoRI) to 187889 (HindIII) with a
replacement of the MCMV enhancer sequences (MCMV nt 182940 to 184086;
48 to 1191 relative to the MCMV ie1/ie3 transcription start site) by the
corresponding sequences of the HCMV enhancer (52 to 667 relative to the
HCMV ie1/ie2 transcription start site) (2). In order to introduce the HCMV
enhancer sequences into the MCMV BAC pSM3fr, the 1.0-kbp MluI fragment of
plasmid pEnhDel (2) was replaced with the 2.1-kbp MluI fragment of plasmid
pIE111H, and an 8.6-kbp SalI fragment of the resulting plasmid was then trans-
ferred to the shuttle plasmid pST76-ASacB.
The four putative NF-B binding sites in the 613-bp HCMV enhancer se-
quence of plasmid pIE111H-NF-B were destroyed by site-directed mutagenesis.
Unique restriction sites were introduced during mutagenesis (98 to 103 StuI,
161 to 166 KpnI, and 265 to 270 and 416 to 421 BglII), and mutated
sequences are illustrated in Fig. 1A. A 2.1-kbp MluI-fragment carrying the
mutated NF-B response elements was transferred into pEnhDel and finally into
pST76-ASacB exactly as described for the corresponding DNA fragment of
pIE111H.
Mutagenesis of the full-length MCMV BAC plasmid pSM3fr (51) was per-
formed in the Escherichia coli strain CBTS by using a two-step replacement
method (34, 38) with the modifications recently described (2, 5, 51). BAC DNA
was prepared from 10-ml overnight cultures by the alkaline lysis procedure (31)
and subjected to treatment with appropriate restriction endonucleases followed
by agarose gel electrophoresis. Primers dN (5	-GCG GCC GCT GCA TAC GTT
GTA TCC ATA TC-3	) and dBlp (5	-CGC TCA GCC CGC CCA TTT GCG
TCA ATG GGG-3	) were used to amplify the authentic or mutant 616-bp
HCMV enhancer fragments that were inserted into the BACs MCMV-ES and
MCMV-ES.NF-B, respectively. Ten nanograms of the BAC DNA was used as
the template, and PCR conditions were as follows: 1 cycle at 96°C for 3 min; 30
cycles of 30 s at 96°C, 45 s at 60°C, and 30 s at 72°C; and 1 cycle at 72°C for 10
min. Amplified DNA products were isolated by using a PCR purification kit
(Qiagen, Hilden, Germany), and 1/10 of the eluate was subjected to digestion
with endonuclease BglII or KpnI, followed by electrophoretic separation in a
1.2% low-melting-point agarose gel. BACs were transfected into MEFs by using
the calcium phosphate transfection technique. Six hours posttransfection, cells
were treated with glycerol (15% glycerol in HEPES-buffered saline) for 3 min as
described previously (38). The progeny virus that originated from these cultures
was harvested when 100% cytopathic effect was observed. BAC-derived viruses
were amplified, subjected to three rounds of plaque purification, and used for the
preparation of high-titer stocks. The integrity of the viruses generated was con-
firmed by restriction enzyme analysis of the corresponding genomes and se-
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quencing of the enhancer regions (data not shown). Enhancer sequences were as
expected, except for a one-base deletion in MCMV-ES.NF-B corresponding to
nt position 424 (relative to the transcription start site of the HCMV MIEP).
Construction of IBM cell lines. NHDF IBM cells were described previ-
ously (4). NIH 3T3 and J774 IBM cells were generated by multiple rounds of
transduction with IBM-expressing retrovirus, a gift from I. Verma (50), and
stable cell pools were selected with G418 (0.8 mg/ml) as described previously (4)
in order to reduce the possibility of artifacts arising from clonal populations.
Determination of CMV replication kinetics. Cell lines were infected at 
80%
confluency (
105 cells in a 12-well dish) with CMV for 2 h (350-l volume).
Virus was aspirated, and cells were then washed twice and incubated in growth
medium. Cell supernatants were collected at various times postinfection, centri-
fuged briefly to pellet any cell debris, and frozen at 80°C. Viral titers were then
determined by limiting-dilution plaque assay on NHDF (HCMV) or NIH 3T3
cells (MCMV) by standard methods.
Analysis of NF-B activation. For analysis of ICAM-1 upregulation on the cell
surface, NHDF, NIH 3T3, or J774 LXSN or IBM cells (
105) were treated
with 1 nM human TNF (gift of J. Browning; Biogen, Boston, Mass.) or lympho-
toxin alpha (LT) for 
24 h. Cells were then dislodged with 5 mM EDTA in
phosphate-buffered saline and analyzed for cell surface expression of human
ICAM-1 (NHDF, mAB2146; Chemicon, Temecula, Calif.) or murine ICAM-1
(NIH 3T3 or J774 cells, clone 3E2; BD Biosciences, San Diego, Calif.) by flow
cytometry as described previously (4).
For electrophoretic mobility shift assay (EMSA) analysis of p50/p65 NF-B
activation, cells (
3  106) were treated with TNF, LT, or CMV at the
indicated concentrations or MOI for 2 h. Cells were harvested by scraping and
lysed in 500 l of cytoplasmic extraction buffer A (20 mM HEPES [pH 7.55], 10
mM KCl, 0.1 mM EDTA, 1 mM dithiothreitol, 1 mM orthovanadate, 1 mM
phenylmethylsulfonyl fluoride, leupeptin, and aprotinin) on ice for 15 min. NP-40
was added to a final concentration of 0.5%, and the cell nuclei were pelleted by
centrifugation at 18,000  g for 1 min in a microcentrifuge. The nuclear pellet
was lysed in 50 l of nuclear lysis buffer B (20 mM HEPES [pH 7.55], 400 mM
NaCl, 0.1 mM EDTA, 1 mM dithiothreitol, leupeptin, and aprotinin) and vor-
texed gently for 
1 h at 4°C, and lysates were cleared by centrifugation for 5 min
at 18,000  g.
Fifteen microliters of buffer B containing 50% glycerol was added to the
cleared lysate, and protein concentrations were determined by using the bovine
serum albumin protein assay (Pierce, Rockford, Ill.) following the manufactur-
er’s protocol. Ten micrograms of total protein for each sample was incubated
with 32P-labeled (polynucleotide kinase) double-stranded oligonucleotides
(20,000 cpm/sample) corresponding to the NF-B binding site in the immuno-
globulin  light-chain enhancer (sense, 5-ATGTGAGGGGACTTTCC CAGG
C-3	; antisense, 5	-GCCTGGGAAAGTCCCCTCAACT-3	) and 100 ng of poly-
(dI:C) per ml and then analyzed by nondenaturing polyacrylamide gel
electrophoresis (5% polyacrylamide gel). The dried gel was exposed to film, and
the bands were visualized by autoradiography. Unlabeled oligonucleotides (200
ng) were used as a competitor to show binding specificity. Supershifts were
performed with both anti-p65 (Santa Cruz Biotech, Santa Cruz, Calif.) and
anti-p50 (Upstate, Lake Placid, N.Y.) antibodies to verify the identity of the
p50/p65 heterodimer.
Analysis of CMV IE expression. For analysis of ie1 expression, cells were
infected with HCMV (AD169-ATCC) or MCMV and harvested at various times
postinfection for isolation of RNA and subsequent analysis by real-time PCR as
described previously (4). Primer sequences designed to amplify within exon 4 of
ie1 were as follows: HCMV, 5	-CATCCACACTAGGAGAGCAGACTC-3	 and
5	-GCATGAAGGTCTTTGCCCAG-3	; MCMV, 5	-AGCTGTTGGTGGTGT
CACTCAA-3	 and 5	-GGCTGGGACTCATCTTCTTCAG-3	. For MCMV ie3
(exon 5), the primer sequences used were 5	-GCCCCAACCTGTCCATCTC-3	
and 5	-CCTGCTGTGGTTAATGGGCT-3	. For analysis of IE1 protein levels,
infected NHDF (
105) were harvested at various time points and subjected to
Western blot analysis using anti-IE1 monoclonal antibodies (mix of clones 63 and
27; kind gift of W. Britt) as described previously (4).
FIG. 1. Mutagenesis of the HCMV-MIEP NF-B binding sites in
hMCMV-ES. (A) Organization of the MIE regions of the constructed
MCMV BAC genomes. The HindIII map of the MCMV genome is
given at the top. The expanded map below represents the MIE region
of MCMV with the enhancer (gray box) and the exon-intron structure
of the ie1, ie2, and ie3 genes indicated. Coding and noncoding exons
are depicted as black and white boxes, respectively. The BAC plasmids
hMCMV-ES and hMCMV-ES.NF-B carry a 616-bp fragment (white
rectangle) from the HCMV MIE promoter in replacement of the
MCMV enhancer. In hMCMV-ES.NF-B, the NF-B binding sites
were mutated, introducing unique restriction sites (98 to 103 StuI,
161 to 166 KpnI, and 265 to 270 and 416 to 421 BglII),
which are indicated by asterisks or black bars. The sizes of the expected
HindIII L fragments of the MCMV BAC genomes and the sizes of the
expected BglII and KpnI fragments of the PCR-amplified HCMV en-
hancer (with primers shown with short arrows flanking the enhancer)
are indicated by the arrows. Coordinates are given relative to the
MCMV ie1/ie2 transcription start site. The diagrams are not drawn to
scale. (B) Ethidium bromide-stained agarose gel of HindIII-digested
MCMV BAC plasmid (1), hMCMV-ES (2), and hMCMV-ES.NF-B
(3). The names and sizes of the HindIII fragments of the MCMV
genome are indicated in the margins. (C) To verify successful mu-
tagenesis of NF-B sites, enhancer sequences were amplified from
MCMV-ES (lanes 1 and 3), and hMCMV-ES.NF-B (lanes 2 and 4)
BACs by PCR. The amplified products were digested with restriction
enzyme BglII (lanes 1 and 2) or KpnI (lanes 3 and 4), and the resulting
DNA fragments were separated by gel electrophoresis.
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RESULTS
NF-B response elements in the MIEP are not required for
replication of MCMV in fibroblasts. Previous studies have
shown that infection of fibroblasts with MCMV results in ac-
tivation of NF-B (18, 19), similar to that seen for HCMV, and
raises the question of whether this activation is required for
efficient MCMV replication. In the following set of experi-
ments, we first sought to test whether the NF-B binding sites
in the MIEP contribute to MCMV replication in fibroblasts by
introducing point mutations that abolish the ability of NF-B
to bind to the enhancer. The MCMV enhancer has over 12
consensus NF-B response elements contained within a highly
repetitive sequence that is prohibitive for generating site-di-
rected mutations. For this and other reasons, we previously
generated a recombinant MCMV in which the native MIEP
enhancer has been replaced by the less repetitive HCMV en-
hancer (2). The HCMV enhancer, unlike its mouse counter-
part, contains only four NF-B binding sites. Importantly, this
recombinant “enhancer swap” virus (hMCMV-ES) exhibits in-
fectious kinetics similar to that of wild-type MCMV upon in-
fection of murine fibroblasts (2). To directly investigate the
role of the NF-B binding sites present in the HCMV en-
hancer on viral replication, an hMCMV-ES mutant was gen-
erated (hMCMV-ES.NF-B) that contained mutations known
to abolish NF-B binding within all four sites. The viral mutant
was constructed by using the previously described CMV BAC
system (34), and a schematic representation of the parental
and recombinant viruses is shown in Fig. 1A.
Unique restriction sites were introduced when mutating the
NF-B binding sites and were used to confirm the successful
construction of hMCMV-ES.NF-B by restriction digestion.
To verify the genomic structure of the recombinant BACs used
in the study, their HindIII restriction patterns were analyzed.
As expected (Fig. 1B), the natural 7.2-kbp MCMV HindIII L
fragment of the wild-type MCMV BAC plasmid was replaced
by a new 6.7-kbp HindIII L fragment in the recombinant
hMCMV-ES and hMCMV-ES.NF-B plasmids (compare lane
1 with lanes 2 and 3). To confirm that the intended mutations
were introduced in the BAC plasmid hMCMV-ES.NF-B, a
632-bp fragment corresponding to the HCMV enhancer re-
gions of hMCMV-ES and hMCMV-ES.NF-B was PCR am-
plified and subsequently digested with BglII or KpnI (Fig. 1C)
(see Materials and Methods for details). When the PCR-am-
plified product from hMCMV-ES.NF-B was digested with
BglII, two major bands of 150 and around 230 bp (the latter
corresponding to the predicted 222- and 259-bp digested frag-
ments) were detected. Similarly, digestion of the PCR-ampli-
fied product from hMCMV-ES.NF-B with KpnI resulted in
the two expected fragments of 122 and 510 bp. In contrast, the
PCR-amplified product from hMCMV-ES was not altered af-
ter digestion with restriction enzymes BglII or KpnI. Mutations
were also confirmed by sequencing the entire enhancer and
flanking regions of the BAC (data not shown). Altogether,
these results indicate the integrity of the BAC constructs and
the successful disruption of the NF-B binding sites within the
enhancer region of the hMCMV-ES.NF-B BAC.
Recombinant viruses were generated by transfection of the
constructed BACs into NIH 3T3 cells, collection of viral su-
pernatants, and three subsequent rounds of plaque purifica-
tion. hMCMV-ES.NF-B-derived virus was then tested to de-
termine whether the mutations introduced in the NF-B
binding sites altered the ability of the virus to grow in cell
culture. For this purpose, NIH 3T3 cells were infected with the
parental hMCMV-ES and hMCMV-ES.NF-B at a low MOI
of 0.1, and viral titers in the supernatants of the cultures were
determined at various times postinfection. hMCMV-
ES.NF-B exhibited no growth defects when compared to the
parental virus (Fig. 2). Since the genetic abolition of all four
consensus NF-B sites within the enhancer region had no
negative effect on CMV growth, we conclude that the NF-B
binding sites in the enhancer are nonessential for potentiating
MCMV replication in cultured fibroblasts.
The canonical NF-B pathway is not required for replica-
tion of murine CMV in fibroblast- or macrophage-derived cell
lines. In addition to mutating the NF-B response elements in
the MIEP, a second approach, which avoids causing mutations
in the virus, was also taken to address the role of NF-B in
MCMV replication. In order to determine whether NF-B
activation was directly or indirectly required for MCMV rep-
lication, a dominant negative version of the inhibitor of NF-
B-alpha (IB) that had been mutated at two critical serine
residues (S32 and S36) to alanine (IBM) was utilized (50).
An IBM-expressing retroviral vector, or control vector
(LXSN), was used to transduce both NIH 3T3 and J774 cells,
murine fibroblast- and macrophage-derived cell lines, respec-
tively. Stable cell pools expressing IBM were selected after
transduction to avoid possible artifacts arising from single-cell
clones. NF-B-mediated transcription was shown to be inhib-
ited by the use of a flow cytometry-based assay examining the
ability of the NF-B-responsive gene ICAM-1 (21) to be up-
regulated in response to treatment of cells with the TNF family
ligand, LT (Fig. 3A). LT binds to TNF receptor 1 (TNFR-1)
(52), which is expressed on the surface of most cells at low
levels, resulting in the TNFR-associated factor 2-dependent
activation of NF-B (p50/p65). Both TNF and LT bind
FIG. 2. The MIEP NF-B binding sites are not required for
hMCMV-ES replication in NIH 3T3 cells. NIH 3T3 cells were infected
at an MOI of 0.1 with either hMCMV-ES or hMCMV-ES.NF-B
recombinant virus. Cell supernatants were collected at various days
postinfection, and titers (PFU/ml) were analyzed in triplicate by
plaque assays on NIH 3T3 cells. Error bars represent standard errors
of the means.
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TNFR-1 and activate the canonical NF-B pathway through an
IKK-dependent mechanism. These ligands can also induce
apoptosis in many cell lines, but TNF oftentimes exhibits more
potent apoptotic activity in vitro than does LT (52). NIH 3T3
cells are highly sensitive to apoptosis induced by TNF, as
opposed to J774 cells, which are largely resistant, necessitating
the use of LT as an agonist in these cells to allow detection of
ICAM-1 after a 24-h incubation in cytokine (Fig. 3A). As
expected, based on the observed inhibition of ICAM-1 upregu-
lation, the translocation of p50/p65 NF-B to the nucleus after
treatment of 3T3-IBM cells with LT was inhibited com-
pared to control cells, and this was also the case after infection
with MCMV (Fig. 3B).
After p50/p65 NF-B-mediated nuclear translocation and
transcription was verified to be inhibited, cells were infected
with MCMV (Smith strain) at various MOIs, and the kinetics
of viral replication was compared to that of control cells (Fig.
4). Infections at different MOIs were performed due to previ-
ous results indicating that disruption of ie1 expression shows
no phenotype at high MOI, but replication deficiencies are
unmasked at low MOI (14, 17, 32, 33). No differences in the
ability of MCMV to replicate were seen when IBM was used
to inhibit activation of the canonical NF-B pathway in either
of these cell lines, even at low MOI (Fig. 4).
As an alternative approach to assess the contribution of the
canonical NF-B pathway to MCMV infection, replication of
MCMV was examined in p65/RelA-deficient immortalized
MEFs (p65/ MEFs). Infection was performed at both high
and low MOI, and replication of MCMV in p65/ MEFs was
compared to that in p65/ MEFs (Fig. 5A). No restriction of
MCMV replication was observed in p65/ MEFs at any MOI.
Alternatively, increased levels of MCMV replication were ob-
served at low MOI compared to those of p65/ MEFs derived
from wild-type littermate control mice (3). Consistent with
these results, significantly higher levels of MCMV ie1 and ie3
expression were detected at low MOI in p65/ MEFs, and
these differences were less marked as the MOI was increased
(Fig. 5B). This observation suggests a potentially p65-depen-
dent but IB-independent suppression of MCMV replica-
tion.
Taken together, these data unequivocally show that activa-
tion of the canonical NF-B pathway is nonessential for initi-
ating and promoting MCMV replication or expression from
the MIEP in immortalized fibroblasts or a macrophage cell
line.
FIG. 3. IBM overexpression inhibits p50/p65 NF-B activation
in NIH 3T3 and J774 cells. NIH 3T3 or J774 cells were transduced with
either control (LXSN) or IBM retroviral vector. (A) To verify that
the IBM-expressing cells were inhibited for p50/p65 NF-B-medi-
ated transcription, J774 and 3T3 cells were incubated with1 nM TNF
or LT for 24 h, respectively, and cell surface levels of ICAM-1 (a
NF-B responsive gene) were analyzed by flow cytometry. Dotted
histograms represent binding of isotype control antibody, gray histo-
grams are cells untreated with cytokine, and black histograms are
cytokine-treated cells. (B) Translocation of p50/p65 NF-B to the
nucleus is inhibited in IBM-expressing cells. NIH 3T3 LXSN or
IBM () cells were treated with LT (1 nM) or MCMV (MOI  2)
for 2 h; nuclear extracts were prepared and subjected to EMSA. The
arrow identifies the p50/p65 heterodimer of NF-B. M, mock treated;
cp, addition of unlabeled competitor, NF-B-binding oligonucleotide
probe.
FIG. 4. Replication of MCMV is normal in cells expressing a dom-
inant negative inhibitor of IB. NIH 3T3 (upper two panels) and J774
(lower two panels) control (LXSN) and IBM cells were infected at
either high or low MOI with MCMV, and supernatant was collected at
different times (days or hours) postinfection (dpi and hpi, respec-
tively). MCMV titers (PFU/ml) were determined in triplicate by limit
dilution in NIH 3T3 cells. Error bars represent standard errors of the
means.
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Inhibiting the canonical NF-B pathway has no effect on
human CMV replication in fibroblasts. Numerous studies have
shown that human CMV infection induces activation of NF-B
(9, 10, 45, 54), and the NF-B-responsive elements present in
the MIEP (Fig. 1A) bind NF-B and are responsive to NF-
B-mediated transcriptional enhancement in transient-trans-
fection reporter-based expression assays (45). To investigate
the role of the canonical NF-B pathway for HCMV replica-
tion, we determined growth kinetics of laboratory and clinical
strains upon infection of an NHDF line which expresses
IBM (4). This cell line (NHDF-IBM) shows severely re-
duced levels of IB degradation (4) and ICAM-1 upregula-
tion in response to treatment of cells with TNF when com-
pared to that of a control cell line (NHDF-LXSN) (Fig. 6A).
Importantly, NHDF-IBM cells show no translocation of
p50/p65 NF-B to the nucleus after treatment with TNF or
LT or after infection with HCMV or UV light-inactivated
HCMV (Fig. 6B).
NHDF-IBM cells were compared to NHDF-LXSN cells
for their ability to support replication of HCMV. Infections
were performed at both high and low MOI with two distinct
strains of HCMV, AD169-ATCC and Toledo (Fig. 6C). No
differences were detected in the ability of AD169 to replicate
in NHDF-IBM cells compared to that of control fibroblasts
when infected at either high or low MOI. The Toledo strain of
HCMV was then analyzed because it harbors at least 19 open
reading frames which are not present in AD169 (8), resembling
viral clinical isolates. As was seen for AD169, no differences in
the replication of Toledo were detected when comparing the
two NHDF lines (Fig. 6B). Based on these results, we conclude
that the blockade of the canonical NF-B pathway by overex-
pressing the IBM in NHDF does not alter viral replication.
Expression of HCMV IE1 in infected cells does not require
NF-B. Although HCMV replicates as well in NHDF-IBM
cells as it does in control fibroblasts, previous reports suggest
that the levels of ie1 expression might be lower in cells deficient
in NF-B activation (9, 43, 45, 49). Therefore, the levels of IE1
message and protein were compared in NHDF-IBM and
-LXSN cells infected with HCMV at a low MOI (0.005 and 0.1,
respectively). IE1 message levels were roughly equivalent in
NHDF-IBM and NHDF-LXSN cells as determined by real-
time PCR at various times postinfection, indicating that the
canonical NF-B pathway is not required for transactivation of
the ie1 promoter-enhancer during viral replication in fibro-
blasts (Fig. 7A). IE1 protein levels were also compared in
HCMV-infected NHDF-IBM and -LXSN cells. In order to
detect IE1 at early times postinfection (5 or 8 h) fibroblasts
FIG. 5. Mouse CMV replication is increased in p65-deficient fibro-
blasts. (A) p65-deficient (p65/) and control (p65/) immortalized
MEFs were infected with MCMV at several different MOIs, and su-
pernatant was collected at various days postinfection for analysis of
viral PFU produced. Titers were determined in triplicate in NIH 3T3
cells, and error bars represent standard errors of the means. (B) The
relative level of MCMV ie1 and ie3 expression in p65/ MEFs was
compared to that of p65/ MEFs at various times postinfection at
several different MOI by real-time PCR. Values are representative of
three independent experiments, and error bars represent the standard
errors of the means.
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needed to be infected at a relatively high MOI (0.5), taking into
consideration that infecting at higher MOI is not ideal for ana-
lyzing effects on MIEP activity. When IE1 levels were compared
in IBM- versus LXSN-infected cells, no significant differences
were seen (Fig. 7B), consistent with the results obtained when
analyzing ie1 mRNA (Fig. 7A). At lower MOI (0.02), similar
levels of IE1 were also seen when analyzed at later times (24 h
postinfection) (Fig. 7B). Finally, treatment of HCMV-infected
IBM and LXSN fibroblasts with TNF, a strong activator of
NF-B, showed no differential effects on IE1 expression, although
FIG. 6. The canonical NF-B pathway is not required for replication
of human CMV in fibroblasts. (A) NHDF were transduced with control
(LXSN) or IBM retroviral vector. Cells were examined for upregula-
tion of ICAM-1 by flow cytometry after incubation with 1 nM TNF.
Dotted histogram represents binding of isotype control antibody. (B) Nu-
clear extracts from NHDF-LXSN or -IBM () cells treated with TNF
(1 nM) or LT (1 nM) or infected with HCMV or UV light-inactivated
HCMV (uvHCMV; MOI, 5 or 2) for 2 h were subjected to EMSA to
analyze the level of p50/p65 NF-B (indicated by the arrow) translocation
to the nucleus. (C) NHDF-LXSN or -IBM cells were infected at an
MOI of 0.01 or 2 with HCMV strain AD169 or Toledo. Cell supernatant
was collected at various days postinfection, and viral titers (PFU/ml) were
determined in triplicate by plaque assays in NHDF. Error bars represent
standard errors of the means.
FIG. 7. Inhibition of the canonical NF-B pathway does not inhibit
expression of HCMV IE1. (A) NHDF-LXSN or -IBM cells were
infected at an MOI of 0.005 (dark bars) or 0.1 (light bars) and were
harvested at various hours postinfection (hpi) for analysis of ie1 ex-
pression by real-time PCR. Results represent the relative amount of
ie1 expression in IBM cells compared to that of control cells
(LXSN) at the various times. Values are averaged data from three
independent experiments, and error bars represent the standard errors
of the means. (B) NHDF-LXSN or -IBM cells were infected with
HCMV at an MOI of 0.5 or 0.02. Cells were harvested at various hpi
for analysis of IE1 protein levels by Western blotting. For samples
treated at an MOI of 0.02, LXSN-infected cells are shown in the left
lane, and IBM cells are shown in the right. (C) NHDF-LXSN (first
two lanes of each time point) or -IBM cells (second two lanes of
each time point) were infected with HCMV at an MOI of 2, and cells
were harvested at various hpi for analysis of IE1 protein levels by
Western blot. For each time point, cells were either treated with ()
1 nM TNF or were not ().
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slightly lower levels of IE1 were seen at 6 h postinfection in both
cell lines compared to those found in untreated samples (Fig. 7C).
These results further confirm that inhibition of the canonical
NF-B pathway does not restrict HCMV gene expression in cul-
tured fibroblasts.
DISCUSSION
The role of NF-B during viral infection is critical for
mounting antiviral immune responses through activation of
various host inflammatory genes (15). In this regard, it would
seem deleterious for viruses to trigger NF-B upon infection of
host cells. However, several viruses, including CMV (45, 55),
herpes simplex virus type 1 (39), human immunodeficiency
virus (12), and others have been reported to utilize NF-B to
their advantage by incorporating NF-B response elements
into their genomes. In the case of CMV, the activation of
NF-B upon infection has been proposed to be important for
modulating expression of viral immediate-early genes (45, 55).
Although it is well established that NF-B is activated by CMV
upon infection of cells in culture, little has been done to ad-
dress the importance of this key transcription factor in viral
replication. In this study we have used several different ap-
proaches to test directly whether NF-B positively contributes
to the CMV transcription-replication cycle in vitro. We present
multiple lines of evidence that show a remarkably neutral en-
gagement of the pathway, and in certain experiments a mod-
erate negative contribution to CMV replication can be ob-
served. These findings are more consistent with the notion that
CMV effectively buffers itself against a strong innate immune
response to an acute infection.
In hMCMV-ES, the mutation of the NF-B binding sites in
the HCMV MIEP did not restrict viral replication in NIH 3T3
cells. In this connection, it is worth noting that consensus
NF-B binding sites are present only in the MIEP enhancer
region of the MCMV genome (44) (P. Ghazal, unpublished
observation). We further analyzed the contribution of the ca-
nonical, or classical, NF-B pathway by using dominant nega-
tive inhibitors of IB and immortalized p65/RelA-deficient
fibroblasts. Infection of fibroblasts by CMV has been shown to
activate the translocation of transcriptionally active p50/p65 to
the nucleus (10, 19, 27) and to induce activation of the p50 and
p65 promoters by IE1 (19, 54, 55). Overexpression of HCMV
IE1 has also recently been reported to induce transcription of
the NF-B family member RelB (23). Our results support a
neutral or redundant role for the canonical NF-B pathway for
CMV replication in cultured cells. In fact, MCMV replicated
significantly better in fibroblasts lacking p65 when infection
was performed at low MOI. Expression of ie1 and ie3 was also
significantly higher in p65/ MEFs infected at low MOI,
consistent with the increases seen in viral titers. In this regard,
it appears that p65 plays an inhibitory role for MCMV repli-
cation in fibroblasts, and this negative effect is amplified at
lower MOIs. One possible explanation for this result is that
innate cellular defenses to MCMV infection are compromised
in p65-deficient fibroblasts. We found that induction of beta
interferon (IFN-) by MCMV is 
40-fold lower in p65/
fibroblasts; however, the addition of neutralizing IFN- anti-
body to the supernatant had no effect (C. Benedict, unpub-
lished observation). Our inability to detect a role for the lower
alpha/beta IFN levels being responsible for the increased CMV
replication in p65-deficient cells is consistent with our obser-
vations that overexpression of IBM also inhibits induction of
IFN- (4), but no significant increases in CMV replication are
observed in these cell lines. Taken together, these data suggest
a potential dominant role for p65 in suppressing CMV repli-
cation, possibly independent of IB, and studies to further
elucidate this mechanism are currently under way.
It is worthwhile to note that we cannot rule out the possi-
bility that during the process of immortalization, p65/ MEFs
may have compensated for the lack of p65 by hyperinduction of
other NF-B family members and that this may contribute to
the increased levels of CMV replication and gene expression.
However, we did observe increased sensitivity to TNF-medi-
ated apoptosis of immortalized p65/ MEFs compared to
that of p65/ MEFs as originally reported by Beg and Balti-
more (3) as well as for 3T3-IBM cells (C. Benedict, unpub-
lished observations), indicating an inhibition of cell survival
gene induction by NF-B in these cell lines. Also noteworthy is
the fact that although cells inhibited for activation of the ca-
nonical NF-B pathway often show increased sensitivity to
apoptosis mediated by TNF or other stimuli, MCMV replica-
tion is not inhibited. In fact, significantly increased replication
is seen in p65/ MEFs at low MOI, suggesting that induction
of apoptosis is not a rate limiting factor for replication of
MCMV in fibroblasts as has been reported for herpes simplex
virus (16).
HCMV engages direct interactions with the cellular tran-
scriptional regulatory network through various regulatory ele-
ments (reviewed in references 35 and 37). The consortium of
host transcription factors which bind the MIEP is likely to vary
based on the cell type, differentiation state, and activation
status, to name a few. Our present study has concentrated on
assessing the contribution of NF-B to CMV replication as
opposed to its role in modulating expression from plasmids
containing MIEP sequences. Our data demonstrate that, in the
context of an infection, the contribution of NF-B is redundant
in cultured cells, revealing a highly robust regulatory network
determining the expression state of CMV, and these findings
should be considered when forming conclusions based on re-
sults achieved in more isolated systems.
Although NF-B does not appear to be required for repli-
cation of human or murine CMV in fibroblasts, it is premature
to extrapolate from these data or draw conclusions regarding
the contribution of NF-B to CMV pathogenesis in vivo. The
life cycle of CMV, as for all herpesviruses, may be subdivided
into two major phases. First, there is the initial, acute infection
which lasts only a few weeks and allows CMV to seed various
host organs; then comes the lifelong, latent phase during which
a competent immune system keeps viral replication largely in
check with sporadic periods of reactivation in select tissues (28,
29). HCMV and MCMV have been reported to establish la-
tency in cells of the monocyte lineage (22, 41), and activation
of NF-B in these cells may contribute to reactivation of viral
replication under certain circumstances of inflammation. Be-
cause the intracellular milieu of host factors during active
CMV infection is not likely to be similar in latently infected
cells in which active viral replication is not occurring, it is not
unreasonable to speculate that the factors which regulate ie
gene expression would be different in these two situations. In
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addition, the differentiation state of infected cells is also likely
to play a role in NF-B’s ability to regulate CMV ie expression
due to the presence of specific inhibitory factors (42). Impor-
tantly, the hMCMV-ES recombinant virus system will allow us
to directly address these questions in vivo.
Through this connection, we have recently shown that the
enhancer is absolutely essential for in vivo growth (14), indi-
cating that the cellular network of transcriptional regulators of
the MIEP has a crucial role in establishing an infection. The
present contribution provides new insights into the nature and
behavior of this network. The striking observation that the
CMV enhancer is insensitive to elimination of NF-B under-
scores the significance of the density of regulatory interactions
within the network and thus its inherent robustness. In evolu-
tionary terms, robustness of the CMV enhancer would confer
functional flexibility, helping to make the virus resistant to the
deleterious effects of mutations in an essential control region;
consequently, the virus is highly adaptive. This finding may
provide an explanation for the relatively high sequence diver-
gence between the MIEPs among the different species mem-
bers of the CMV family. At the functional level, and in the
context of an acute infection, a robust enhancer would allow
flexibility to operate efficiently under various cellular condi-
tions, possibly providing a higher degree of autonomy from
cellular factor constraints upon infection.
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